Phase I NAVIGATOR Trial of Avapritinib in Patients With Metastatic GIST Harboring PDGFRA Exon 18 Mutations or as Fourth-line or Higher Therapy

May 31 - June 4, 2019; Chicago, Illinois
Avapritinib is active in patients with advanced GIST harboring PDGFRA Exon 18 mutations and in those who received ≥ 3 lines of prior therapies.
Format: Microsoft PowerPoint (.ppt)
File Size: 186 KB
Released: June 5, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Blueprint Medicines
Celgene Corporation
Taiho Oncology Inc.

Related Content

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for gastrointestinal cancer

Allison M. Cushman-Vokoun, MD, PhD John L. Marshall, MD Released: August 5, 2021

Video of a live Clinical Care Options (CCO) webinar on immune checkpoint inhibitors for HCC and other hepatobiliary cancers

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Expert review of key data in GI cancers from the 2021 ASCO annual meeting, from Clinical Care Options (CCO)

Manish A. Shah, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue